Abstract
e18503Background: Currently, no PD-1/PD-L1 inhibitors have been approved by the Chinese FDA. Such care disparities definitely limit the therapeutic opportunities of Chinese cancer patients. We cond...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
